- Oops!Something went wrong.Please try again later.
- Oops!Something went wrong.Please try again later.
BALTIMORE, MD / ACCESSWIRE / August 19, 2021 / Goldman Small Cap Research, a stock market research firm specializing in the small cap and microcap sectors, announced today that it has published released a new research report on PetVivo Holdings, Inc., (NASDAQ:PETV). PetVivo is an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices for companion animals. To view the new research report, or other PetVivo research, along with disclosures and disclaimers, or to download it in its entirety, please visit https://bit.ly/37X3NHK.
In the Opportunity Research report, analyst Rob Goldman discusses how PetVivo could emerge as the standard of care in the multi-billion dollar osteoarthritis market for companion animals as well as the fastest growing company in the animal health sector, overall.
Long History of Success, Strong Safety Profile
Goldman noted, "PetVivo Holdings is well-positioned to emerge as the standard of care for the treatment of osteoarthritis in dogs and horses and other companion animals. This unmet need represents an estimated $4.4B combined annual market. PETV's flagship platform has a long history of success, addresses the underlying cause of OA, and has a strong safety profile. Given its efficacy, affordability, and the emergence of new revenue streams for veterinarians, PETV offers a compelling therapy."
Major Growth in Pet Health Market
"The pet health market is enjoying enviable growth as pet owners are spending large sums for pet medical care, serving as a major driver for PETV," noted Goldman. "Plus, the recent broad adoption of pet insurance has also emerged as a key catalyst."
New Funding, NASDAQ Up-List Could Accelerate Growth
"Following a major funding and up-list to NASDAQ, PETV is set to commence a full-scale sales and marketing effort to accelerate sales growth. Management has already attracted key KOLs and influencers, aided by therapeutic success with over 100 dogs and horses. Against this backdrop, we believe that our model suggests PETV could be the fastest growing animal health stock. Thus, we project revenue will grow from $252K in FY22 to $11.5M in fiscal FY24," stated Goldman.
PETV Trades at Major Discount to Peer Group
Goldman concluded, "Trading at a discount to the peer group's average price/sales multiple, our 12-month price target is a substantial rise from current levels. Plus, given our expected growth rate, PETV could eventually trade at a premium to the group."
About Goldman Small Cap Research: Founded in 2009 by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces sponsored and non-sponsored small cap and microcap stock research reports, articles, stock market blogs, and popular investment newsletters.
Goldman Small Cap Research is not in any way affiliated with Goldman Sachs & Co.
This press release contains excerpts of our most recently published research report on PetVivo Holdings, Inc. The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy. Goldman Small Cap Research relied solely upon information derived from PetVivo Holdings, Inc. ("the Company"). The information includes authorized press releases or legal disclosures made in their filings with the U.S. Securities and Exchange Commission http://www.sec.gov.
Separate from the factual content of our report on the Company, we may from time to time include our own opinions about the Company, its business, markets, and opportunities. Any opinions we may offer about the Company are solely our own, and are made in reliance upon our rights under the First Amendment to the U.S. Constitution, and are provided solely for the general opinionated discussion of our readers. Our opinions should not be considered to be complete, precise, accurate, or current investment advice. Statements herein may contain forward-looking statements and are subject to significant risks and uncertainties affecting results.
A Goldman Small Cap Research report, update, newsletter, article, trading alert, corporate profile, sector or industry snapshot, podcast interview, or press release is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed and is to be used for informational purposes only. Please read all associated full disclosures, disclaimers, and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other regulatory agency. A Speculative Buy rating for our covered companies is defined as a company that we believe exhibits the potential to generate outsized returns despite inherent, above-average business, market, or financial risk. To download this research report or any of our research, view our disclosures and disclaimers, or for more information, visit www.goldmanresearch.com. Goldman Small Cap Research was not compensated for the production of this research report. From 2016-2019, GSCR's principal was compensated by Marble Arch Research Inc. to produce reports and updates on PETV on behalf of Marble Arch Research Inc. and under its banner. In the future, GSCR may be compensated by the Company or a third party for research report production.
Goldman Small Cap Research
Rob Goldman, Analyst
SOURCE: Goldman Small Cap Research
View source version on accesswire.com: